Driving diagnostic certainty for life-changing decisions, we push the boundaries of medical science to deliver the world’s largest menu of more than 250 pathology lab assays and detection products. Every assay we develop is designed with the highest quality in mind—so you can consistently deliver reliable results. Roche antibodies are ready-to-use on VENTANA® fully-automated immunohistochemistry/in situ hybridization (IHC/ISH) instruments, increasing lab efficiency and reducing the time-to-result and resources required with manual or semi-automated solutions.
Scientific validity: Rigorous scientific evaluation and assessment is the first development requirement for every assay in our pipeline
Analytical performance: We comprehensively assess the ability of every assay to correctly and sustainably detect and/or measure a particular analyte, including analytical sensitivity, specificity, precision (repeatability & reproducibility), and accuracy
Clinical performance: A feasibility study, including a minimum of at least15 assay parameters and 20 tissue types, is completed for every assay we develop—ensuring robust performance in customers’ hands across sample types, instruments, and other real-world variables
In addition to a full range of diagnostic tests across key disease areas, only Roche offers the broadest menu of high medical value assays and innovations that deliver new levels of capability and confidence for labs and pathologists.1
The quality and clinical value of every VENTANA® assay* begins in development with our proven design controls–to deliver diagnostic confidence for life-changing decisions through:
Clinical benefit: With proven accuracy, our assays help you deliver the right test with clinical confidence and in a timely manner.
Analytical advantage: Highly specific and sensitive antibodies, accurate probes, and powerful detection systems help you diagnose precisely and confidently.
Testing efficiency: Our comprehensive solutions deliver fully automated assays on robust platforms, with digital pathology and workflow solutions that free up resources, help minimize labor costs, and reduce time to results.
More laboratories choose Roche pathology lab assays for quality than any other provider.2
Because we are committed to helping you drive diagnostic certainty with every answer you provide, we employ an unprecedented team of over 50 pathologists and disease specialists who evaluate every assay, at every stage of development, beginning with ideation and continuing through the life of the product.3
IHC and ISH analysis provides important information related to tumor biology, helps profile breast cancer subtypes, and may improve treatment decisions.4 As the leader in breast cancer diagnostics, Roche offers numerous cancer diagnostic assays that enable pathology labs to deliver accurate results with confidence. We provide a robust menu of over 25 breast cancer diagnostic assays.
With proven accuracy, VENTANA breast cancer diagnostic assays provide timely and confident clinical results. Our robust assays, delivered on fully automated platforms, integrate with digital pathology and workflow solutions. By helping to free up resources, lower labor costs, and accelerate time to results, our comprehensive breast cancer workflow enhances operational effectiveness while enabling you to deliver the right test for each patient.
Melanoma is a malignancy of the melanocytes, and histology is the gold standard for distinguishing malignant cells from benign cells.5 Our robust menu of tools aid in dermatopathology diagnostics and treatment.
Roche provides over 50 cornerstone and novel dermatopathology ready-to-use reagents, including key IHC and fluorescein Isothiocyanate (FITC) antibodies, which aid in melanoma diagnosis, basal cell carcinoma diagnosis, squamous cell carcinoma diagnosis, and diagnosis of other dermatological malignancies.
For colorectal cancer, testing to identify abnormal tissue growth or symptoms includes physical exams, a stool test to check for blood, blood test to look for anemia, liver enzymes, or biomarkers.6
We offer a robust menu of more than 10 tools to aid in colorectal cancer diagnosis.
Prostate cancer is a major public health concern. It is the most commonly diagnosed cancer in men and the second leading cause of cancer death for men in the U.S.7
We offer a wide menu of more than 10 IHC assays to diagnose and subtype prostate cancer.
Our portfolio of proven molecular and tissue-based tests utilizes the science of human papillomavirus (HPV) and biomarker technology to deliver highly sensitive and specific results,8-10 helping bring more clarity of answers for clinical decisions. The Roche cervical cancer portfolio provides three clinically validated tests to help identify women at risk of cervical cancer and improve detection and confirmation of high-grade disease in a single round of screening.
The right test at the right time helps minimize the potential for over- or under-treatment. With proper vaccination, screening and treatment, no woman should die from cervical cancer.
Roche also offers the first FDA approved IHC companion diagnostic test for epithelial ovarian cancer (EOC),11 enabling a treatment pathway for advanced stage, second line platinum resistant EOC.12
Additionally, Roche offers its VENTANA MMR RxDx Panel, the first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy.13
Hematological cancers vary significantly in both prognosis and aggressiveness, demonstrating a need for tools that assist pathologists in making confident diagnoses and helping to inform clinical decisions.16-18
We offer over 60 cornerstone and novel hematopathology ready-to-use assays, including key IHC antibodies and ISH probes, which aid in lymphoma diagnostics, leukemia diagnostics, myeloma diagnostics, and other hematopoietic malignancies.
Our globally preferred menu now features the new VENTANA® Kappa and Lambda Dual ISH mRNA Probe Cocktail Assay in countries accepting the CE Mark.19 This is the first clinically approved, highly-sensitive ISH test designed to help pathologists differentiate a B-cell malignancy from a normal, reactive response to an infection.20
Lung cancer is a significant global health issue and the leading cause of cancer deaths worldwide. In 2022, there were an estimated 2.4 million new lung cancer cases diagnosed.21
Roche offers the most comprehensive menu22 for lung cancer diagnostics with over 30 solutions. Our assays can assist in the stratification of diseases including non-small cell lung carcinoma (NSCLC), neuroendocrine carcinoma, and their various subtypes.23
Filmed on location in Peru, this short, inspiring documentary intimately explores the power of HPV screening to save and improve women’s lives in Peru. The story is told through the eyes of both patients and healthcare professionals.
